Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PaxMedica Inc PXMD

PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral... see more

Recent & Breaking News (GREY:PXMD)

PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023

ACCESS Newswire October 10, 2023

PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire August 30, 2023

PaxMedica Appoints David Hough M.D. as Chief Medical Officer

GlobeNewswire August 16, 2023

PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update

GlobeNewswire August 9, 2023

PaxMedica to Join Fireside Chat with PCG Advisory Following Positive Top Line Results from PAX-HAT-301 Study

ACCESS Newswire August 8, 2023

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

GlobeNewswire July 24, 2023

PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC

GlobeNewswire July 6, 2023

PaxMedica Comments on Common Stock Volatility

GlobeNewswire June 22, 2023

PaxMedica CEO Interviewed by The BRAIN Foundation

GlobeNewswire June 20, 2023

PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder

GlobeNewswire June 14, 2023

PaxMedica Enters Research Collaboration Agreement With PoloMar Health for Phase II Study in Autism Spectrum Disorder

GlobeNewswire June 8, 2023

PaxMedica Completes HAT-301 Registrational Trial for PAX-101

GlobeNewswire June 1, 2023

PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023

GlobeNewswire May 15, 2023

PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month

GlobeNewswire April 19, 2023

PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results

GlobeNewswire March 29, 2023

PaxMedica Holds Meeting of Scientific Advisory Board

GlobeNewswire March 20, 2023

PaxMedica Releases 2022 Shareholder Letter

GlobeNewswire February 15, 2023

PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners

GlobeNewswire February 3, 2023

PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event

GlobeNewswire January 20, 2023

PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com

GlobeNewswire December 14, 2022